PMID- 34286497
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220307
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 25
IP  - 13
DP  - 2021 Jul
TI  - Research on the improvement of oxidative stress in rats with high-altitude 
      pulmonary hypertension through the participation of irbesartan in regulating 
      intestinal flora.
PG  - 4540-4553
LID - 26247 [pii]
LID - 10.26355/eurrev_202107_26247 [doi]
AB  - OBJECTIVE: High-altitude pulmonary hypertension (HAPH) is one of the diseases 
      with higher occurrence among people living in plateau areas. The possible 
      mechanism of angiotensin II receptor 1 inhibitor irbesartan in improving HAPH was 
      explored from the perspective of intestinal bacterial flora in this study. 
      MATERIALS AND METHODS: A HAPH rat model was established under simulated 
      high-altitude hypobaric hypoxia. The levels of oxidative stress and vasoactive 
      substances were detected after irbesartan intervention, and intestinal flora 
      genomics analysis was performed. RESULTS: High-altitude hypobaric hypoxia-induced 
      the increase in pulmonary artery pressure and left ventricular systolic 
      dysfunction in HAPH model rats, but its effects were alleviated by irbesartan. 
      Changes in the levels of oxidative damage in intestinal tissues, such as the 
      increase in superoxide dismutase and glutathione peroxidase in intestinal tissues 
      and the decrease in malondialdehyde content, were also reversed by irbesartan. 
      The serum levels of angiotensin II, endothelin 1, interleukin-6, and C-reactive 
      protein increased substantially whereas the level of nitric oxide decreased in 
      HAPH model rats. The levels of these vasoconstriction and inflammatory indicators 
      were also reversed after irbesartan intervention. The distribution of intestinal 
      florae in rats was changed by the simulated high-altitude hypoxia environment as 
      manifested by the increased Firmicutes-to-Bacteroidetes ratio (F/B), the 
      increased abundance of Lactobacillaceae and Lachnospiraceae, and the decreased 
      abundance of Prevotellaceae and Desulfovibrionaceae at the family level. However, 
      the changes in F/B ratio and the abundance of these florae were reversed by 
      irbesartan. CONCLUSIONS: Irbesartan can alleviate pulmonary artery pressure and 
      left ventricular relaxation in HAPH model rats, reduce the oxidative damage 
      caused by high-altitude hypoxia, and lower the release of vasoconstrictor factors 
      and inflammatory mediators. These effects might be caused by the increased 
      abundance of Lactobacillaceae and Lachnospiraceae and the decreased abundance of 
      Prevotellaceae and Desulfovibrionaceae in the intestines.
FAU - Nijiati, Y
AU  - Nijiati Y
AD  - College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China. 
      ainiwa@sina.com.
FAU - Maimaitiyiming, D
AU  - Maimaitiyiming D
FAU - Yang, T
AU  - Yang T
FAU - Li, H
AU  - Li H
FAU - Aikemu, A
AU  - Aikemu A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Inflammation Mediators)
RN  - J0E2756Z7N (Irbesartan)
RN  - Pulmonary edema of mountaineers
SB  - IM
MH  - Altitude Sickness/blood/*drug therapy/immunology
MH  - Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use
MH  - Animals
MH  - Disease Models, Animal
MH  - Gastrointestinal Microbiome/*drug effects/immunology
MH  - Humans
MH  - Hypertension, Pulmonary/blood/*drug therapy/immunology
MH  - Inflammation Mediators/blood/metabolism
MH  - Irbesartan/*pharmacology/therapeutic use
MH  - Male
MH  - Oxidative Stress/drug effects/immunology
MH  - Rats
EDAT- 2021/07/22 06:00
MHDA- 2022/03/08 06:00
CRDT- 2021/07/21 06:46
PHST- 2021/07/21 06:46 [entrez]
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
AID - 26247 [pii]
AID - 10.26355/eurrev_202107_26247 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4540-4553. doi: 
      10.26355/eurrev_202107_26247.